Sign in
Username
Password
Lost your password?
Login
Login with Facebook
Login with Google
Login with LinkedIn
(close)
Search for:
Sign in
Register
Country Reports
InFocus
Europe
Asia-Pacific
Americas
Middle East & Africa
Legal & Regulatory
Sign in / Register
Country Reports
Americas
Asia-Pacific
Europe
Middle East & Africa
Vaccines
Legal & Regulatory
Shop
Search for:
Library
Contributions
China
COVID-19
Cell & Gene Therapy
Vaccines
News Releases
Facts & Figures
Directory
Shop
Tagged with AAM
Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and introduces the ‘Secure Our Meds’…
Save
Share
The Long Read: Innovation, Access & Affordability in the USA
A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…
Save
Share
The Value Proposition of Generics & Biosimilars in the USA
AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…
Save
Share
Biosimilar Adoption in the US: Still Lagging Behind Europe
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…
Save
Share
How US Generics Firms are Responding to COVID-19 Supply Chain…
AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the…
Save
Share
USMCA Sets a New Standard for International Trade
Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in…
Save
Share
Opportunities to Fix Medicare Part D
The Association for Accessible Medicines' Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic…
Save
Share
Chip Davis – President & CEO, Association for…
The AAM's Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple…
Save
Share
180-Day Exclusivity: The Key Ingredient in Hatch-Waxman
The AAM's Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry…
Save
Share
After the Prescription Is Written, Another Challenge: Abandonment
The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug…
Save
Share
Interview: Andrea van Elsas – CSO & Hans van Eenennaam…
The CSO and COO of BioNovion talk about the company's recent acquisition by US-based biotech Aduro. BioNovion is a Dutch biopharma specialized in…
Save
Share
Interview: Stefan Braam – CEO, Pluriomics, The Netherlands
Stem cell technology can play a key role in improving the drug discovery process. The CEO of Pluriomics, a biotech company focused on development of…
Save
Share
Page: 1 |
1
2
interviews
{"post_type":["article","interviews","legal_article","facts","infocus","sponsored"],"post_status":"publish","posts_per_page":12,"max_num_pages":-1,"paged":1,"meta_query":[{"key":"related","value":" AAM","compare":"LIKE"}]}
We use cookies to ensure that we give you the best experience on our site. For more info
click here
ACCEPT